Scilex Holding Company (SCLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scilex Holding Company (SCLX) has a cash flow conversion efficiency ratio of 0.004x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.11 Million) by net assets ($-254.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Scilex Holding Company defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Scilex Holding Company - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Scilex Holding Company's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Scilex Holding Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scilex Holding Company ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VHM Ltd
AU:VHM
|
-0.041x |
|
Lay Hong Bhd
KLSE:9385
|
0.094x |
|
Bluebird bio Inc
NASDAQ:BLUE
|
0.751x |
|
ConvaTec Group PLC
LSE:CTEC
|
0.086x |
|
Wooshin System
KO:017370
|
-0.050x |
|
Libental
TA:LBTL
|
-2.455x |
|
Metavista3D Inc.
V:DDD
|
N/A |
|
Auto Trader Group plc
LSE:AUTO
|
0.294x |
Annual Cash Flow Conversion Efficiency for Scilex Holding Company (2020–2025)
The table below shows the annual cash flow conversion efficiency of Scilex Holding Company from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see SCLX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-211.75 Million | $3.82 Million | -0.018x | +82.06% |
| 2024-12-31 | $-192.64 Million | $19.35 Million | -0.100x | -183.88% |
| 2023-12-31 | $-172.94 Million | $-20.71 Million | 0.120x | +120.41% |
| 2022-12-31 | $36.24 Million | $-21.26 Million | -0.587x | -558.16% |
| 2021-12-31 | $-223.88 Million | $-28.66 Million | 0.128x | -42.34% |
| 2020-12-31 | $-141.68 Million | $-31.46 Million | 0.222x | -- |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more